← brief for 2026-11-02 · Slowing decline

Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

Trial No results yet Not peer reviewed

Key takeaways

This is a new trial that is starting. It will test a drug called ABP-671 in people with kidney disease and high uric acid. The study is planned to last 40 weeks. There are no results yet because the trial is just beginning.

Who did this work

Run by Atom Therapeutics Co., Ltd.
Sites: Renal Research Gosford Pty Ltd · Genesis Research services · Paratus Clinical Research Brisbane · Beijing Tsinghua Changgung Hospital · Peking University First Hospital · Xuanwu Hospital Capital Medical University

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-11-02
https://clinicaltrials.gov/study/NCT07323095